Proteostasis, Biogen partner for new Alzheimer’s program
By Staff Writer
Monday, December 9, 2013
Proteostasis Therapeutics Inc. partnered with Biogen Idec to find new drug candidates based on inhibition of Usp14 in a deal worth upward of $200 million. The partnership will pair Proteostasis’ work in protein degradation with Biogen Idec’s expertise in neurodegenerative diseases.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.